ArticleEuropean journal of radiology2022
Organ doses and cancer risk assessment in patients exposed to high doses from recurrent CT exams.
Article in European journal of radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Article
- Preconception computed tomography exposure and risk of stillbirth in a nationwide population based cohort study.Scientific reports · 2025Article
- Optimization of abdominal CT based on a model of total risk minimization by putting radiation risk in perspective with imaging benefit.Communications medicine · 2024Article
- Assessing the inter-observer and intra-observer reliability of radiographic measurements for size-specific dose estimates.BMC medical imaging · 2024Article
- Incidence and Mortality Life-Attributable Risks for Patients Subjected to Recurrent CT Examinations and Cumulative Effective Dose Exceeding 100 mSv.Clinics and practice · 2024Article
- Can clinicians identify community-acquired pneumonia on ultralow-dose CT? A diagnostic accuracy study.Scandinavian journal of trauma, resuscitation and emergency medicine · 2024Article
- Characterizing imaging radiation risk in a population of 8918 patients with recurrent imaging for a better effective dose.Scientific reports · 2024Article
- Evaluation of patient radiation dose and risk of cancer from CT examinations.Radiological physics and technology · 2024Article
- Cumulative Effective Dose During Fluoroscopically Guided Interventions (FGI): Analysis of More Than 5000 FGIs in a Single European Center.Cardiovascular and interventional radiology · 2024Article
- Real-time, acquisition parameter-free voxel-wise patient-specific Monte Carlo dose reconstruction in whole-body CT scanning using deep neural networks.European radiology · 2023Article
- Rhodamine-Conjugated Anti-Stokes Gold Nanoparticles with Higher ROS Quantum Yield as Theranostic Probe to Arrest Cancer and MDR Bacteria.Applied biochemistry and biotechnology · 2023Article
- Establishing local diagnostic reference levels for computed tomography examinations using size-specific dose estimates.Saudi medical journal · 2023Article
- Diagnostic reference level quantities for adult chest and abdomen-pelvis CT examinations: correlation with organ doses.Insights into imaging · 2023Article
- Patients undergoing multipleThe British journal of radiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purposeTo estimate cumulative organ doses and age- and gender-stratified cancer mortality risks in patients undergoing recurrent computed tomography (CT) exams.
methodsCohorts of patients who received cumulative effective dose ≥ 100 mSv were stratified into age and gender groups. Organ doses of 27 organs using Monte Carlo methods were available, and the relative risk model from the Biological Effects of Ionizing Radiation VII (BEIR VII) was used to estimate lifetime attributable cancer mortality risks (LACMR).
resultsOut of the 8956 patients, 6.7% were 16-44 years of age, with median organ doses higher than 200 mGy for stomach and liver, whereas organ doses for nine organs, which included lungs, breasts, colon, red bone marrow, urinary bladder, esophagus, testicles, ovaries, and skin were between 100 and 200 mGy. Thyroid and salivary glands had smaller doses in the range of 45-69 mGy, but the mean dose for each organ was over 100 mGy. The age- and gender-specific median LACMR for the 16-44-years cohort was 0.6 to 0.7 deaths per 100 individuals for males, and 0.8 for females. The mortality estimated figures were highest for patients 16-54 years with slightly lower values for older age groups. Except for the highest age bracket of 75-84 years, the LACMR values for 55-74 years are not lower by orders of magnitude, and thus one cannot ignore risks in this age group.
conclusionsOrgan doses over 100 mGy for most organs and for some organs ≥ 200 mGy with unignorable associated lifetime attributable cancer mortality rates were found.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.